Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome

.blurhash-client-img { display: none !important; }

Open Access

|Mar 2022

Authors

Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey

Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey

Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey

Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey

Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey

Department of Nephrology Dialysis and Transplantation, Gazi University Faculty of Medicine, Ankara, Turkey

DOI: https://doi.org/10.2478/rjim-2021-0034 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749

Language: English

Page range: 56 - 65

Submitted on: Jun 22, 2021

Published on: Mar 17, 2022

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

Related subjects:

© 2022 Hasan H. Yeter, Ulver Derici, Turgay Arinsoy, Kadriye Altok, Yasemin Erten, Galip Guz, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.